Published in Invest Ophthalmol Vis Sci on July 01, 2003
Gamma-synuclein as a marker of retinal ganglion cells. Mol Vis (2008) 1.20
Peroxiredoxin 6 delivery attenuates TNF-alpha-and glutamate-induced retinal ganglion cell death by limiting ROS levels and maintaining Ca2+ homeostasis. Brain Res (2008) 1.16
OPA1 expression in the normal rat retina and optic nerve. J Comp Neurol (2005) 1.06
Agmatine protects retinal ganglion cells from hypoxia-induced apoptosis in transformed rat retinal ganglion cell line. BMC Neurosci (2007) 0.99
Proteasome-caspase-cathepsin sequence leading to tau pathology induced by prostaglandin J2 in neuronal cells. J Neurochem (2009) 0.98
Troglitazone suppresses transforming growth factor beta-mediated fibrogenesis in retinal pigment epithelial cells. Mol Vis (2008) 0.96
Caspase-activated cell-penetrating peptides reveal temporal coupling between endosomal release and apoptosis in an RGC-5 cell model. Bioconjug Chem (2012) 0.94
Researching glutamate - induced cytotoxicity in different cell lines: a comparative/collective analysis/study. Front Cell Neurosci (2015) 0.93
Brain-derived neurotrophic factor released from engineered mesenchymal stem cells attenuates glutamate- and hydrogen peroxide-mediated death of staurosporine-differentiated RGC-5 cells. Exp Eye Res (2009) 0.93
The Wnt signaling pathway protects retinal ganglion cell 5 (RGC-5) cells from elevated pressure. Cell Mol Neurobiol (2011) 0.91
Changes in iron-regulatory proteins in the aged rodent neural retina. Neurobiol Aging (2008) 0.89
Prevention of methylmercury-induced mitochondrial depolarization, glutathione depletion and cell death by 15-deoxy-delta-12,14-prostaglandin J(2). Neurotoxicology (2008) 0.87
Sensitivity of staurosporine-induced differentiated RGC-5 cells to homocysteine. Curr Eye Res (2010) 0.87
NMDA receptor involvement in antidepressant-like effect of pioglitazone in the forced swimming test in mice. Psychopharmacology (Berl) (2012) 0.87
PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies. PPAR Res (2008) 0.86
The role of peroxisome proliferator-activated receptor and effects of its agonist, pioglitazone, on a rat model of optic nerve crush: PPARγ in retinal neuroprotection. PLoS One (2013) 0.86
Etiopathogenesis of cataract: an appraisal. Indian J Ophthalmol (2014) 0.84
Neuroprotection of muscarinic receptor agonist pilocarpine against glutamate-induced apoptosis in retinal neurons. Cell Mol Neurobiol (2008) 0.84
Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes. PPAR Res (2010) 0.83
Human ganglion cells express the alpha-2 adrenergic receptor: relevance to neuroprotection. Br J Ophthalmol (2005) 0.83
Prevention of Oxidative Stress-Induced Retinal Pigment Epithelial Cell Death by the PPARgamma Agonists, 15-Deoxy-Delta 12, 14-Prostaglandin J(2). PPAR Res (2008) 0.83
Effects of mutations and deletions in the human optineurin gene. Springerplus (2014) 0.82
Mechanisms regulating plasminogen activators in transformed retinal ganglion cells. Exp Eye Res (2008) 0.82
Pharmacological protection of retinal pigmented epithelial cells by sulindac involves PPAR-α. Proc Natl Acad Sci U S A (2014) 0.81
Cellular processing of myocilin. PLoS One (2014) 0.81
Herpes Simplex Virus-1 Fine-Tunes Host's Autophagic Response to Infection: A Comprehensive Analysis in Productive Infection Models. PLoS One (2015) 0.78
Molecular Implications of the PPARs in the Diabetic Eye. PPAR Res (2013) 0.78
Staurosporine-induced differentiation of the RGC-5 cell line leads to apoptosis and cell death at the lowest differentiating concentration. Graefes Arch Clin Exp Ophthalmol (2012) 0.77
Neuroprotective effect of astaxanthin against rat retinal ganglion cell death under various stresses that induce apoptosis and necrosis. Mol Vis (2014) 0.76
A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. Alzheimers Dement (2009) 10.21
Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron (2007) 3.98
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol (2012) 3.65
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
Bladder cancer. J Natl Compr Canc Netw (2013) 2.46
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci U S A (2004) 2.15
Hematopoiesis is not clonal in healthy elderly women. Blood (2008) 1.95
Socio-demographic correlates of breast-feeding in urban slums of Chandigarh. Indian J Med Sci (2006) 1.94
Expression of cone-photoreceptor-specific antigens in a cell line derived from retinal tumors in transgenic mice. Invest Ophthalmol Vis Sci (2004) 1.92
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res (2010) 1.78
Acarbose, 17-α-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell (2013) 1.71
Increased beta-secretase activity and expression in rats following transient cerebral ischemia. Brain Res (2004) 1.59
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol (2009) 1.48
Kinase-dependent differentiation of a retinal ganglion cell precursor. Invest Ophthalmol Vis Sci (2006) 1.47
Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. J Biol Chem (2011) 1.41
Hsp27 upregulation by HIF-1 signaling offers protection against retinal ischemia in rats. Invest Ophthalmol Vis Sci (2005) 1.40
Repression of Six3 by a corepressor regulates rhodopsin expression. Proc Natl Acad Sci U S A (2007) 1.38
Quinol-based cyclic antioxidant mechanism in estrogen neuroprotection. Proc Natl Acad Sci U S A (2003) 1.37
Oxidative stress in glaucoma: a burden of evidence. J Glaucoma (2007) 1.36
Testosterone increases neurotoxicity of glutamate in vitro and ischemia-reperfusion injury in an animal model. J Appl Physiol (1985) (2002) 1.35
Induced autoimmunity to heat shock proteins elicits glaucomatous loss of retinal ganglion cell neurons via activated T-cell-derived fas-ligand. J Neurosci (2008) 1.30
Elevated hydrostatic pressure triggers mitochondrial fission and decreases cellular ATP in differentiated RGC-5 cells. Invest Ophthalmol Vis Sci (2007) 1.30
Estrogen attenuates nuclear factor-kappa B activation induced by transient cerebral ischemia. Brain Res (2004) 1.29
Estrogens and progesterone as neuroprotectants: what animal models teach us. Front Biosci (2008) 1.25
The sigma receptor ligand (+)-pentazocine prevents apoptotic retinal ganglion cell death induced in vitro by homocysteine and glutamate. Brain Res Mol Brain Res (2004) 1.23
Estrogens directly potentiate neuronal L-type Ca2+ channels. Proc Natl Acad Sci U S A (2008) 1.22
Cdk5 is involved in NFT-like tauopathy induced by transient cerebral ischemia in female rats. Biochim Biophys Acta (2006) 1.20
17beta-Estradiol attenuates blood-brain barrier disruption induced by cerebral ischemia-reperfusion injury in female rats. Brain Res (2005) 1.18
Neuroprotective effects of an estratriene analog are estrogen receptor independent in vitro and in vivo. Brain Res (2005) 1.16
Oxidative damage to human lens epithelial cells in culture: estrogen protection of mitochondrial potential, ATP, and cell viability. Invest Ophthalmol Vis Sci (2003) 1.15
Light induces programmed cell death by activating multiple independent proteases in a cone photoreceptor cell line. Invest Ophthalmol Vis Sci (2007) 1.13
Retinal ganglion cell line apoptosis induced by hydrostatic pressure. Brain Res (2006) 1.12
Serum deprivation induces apoptotic cell death of transformed rat retinal ganglion cells via mitochondrial signaling pathways. Invest Ophthalmol Vis Sci (2005) 1.11
Testicular cancer. J Natl Compr Canc Netw (2012) 1.11
Analysis of sigma receptor (sigmaR1) expression in retinal ganglion cells cultured under hyperglycemic conditions and in diabetic mice. Brain Res Mol Brain Res (2002) 1.10
Interleukin-10 receptor signaling through STAT-3 regulates the apoptosis of retinal ganglion cells in response to stress. Invest Ophthalmol Vis Sci (2003) 1.10
Novel mechanisms for estrogen-induced neuroprotection. Exp Biol Med (Maywood) (2006) 1.09
Structure-nongenomic neuroprotection relationship of estrogens and estrogen-derived compounds. Pharmacol Ther (2007) 1.09
Transient cerebral ischemia induces site-specific hyperphosphorylation of tau protein. Brain Res (2004) 1.08
Transient cerebral ischemia induces aberrant neuronal cell cycle re-entry and Alzheimer's disease-like tauopathy in female rats. J Biol Chem (2004) 1.07
Neuroprotective effects of 17beta-estradiol and nonfeminizing estrogens against H2O2 toxicity in human neuroblastoma SK-N-SH cells. Mol Pharmacol (2006) 1.06
OPA1 expression in the normal rat retina and optic nerve. J Comp Neurol (2005) 1.06
Calpeptin provides functional neuroprotection to rat retinal ganglion cells following Ca2+ influx. Brain Res (2006) 1.06
Kidney cancer. J Natl Compr Canc Netw (2011) 1.06
Estrogen protects the inner retina from apoptosis and ischemia-induced loss of Vesl-1L/Homer 1c immunoreactive synaptic connections. Invest Ophthalmol Vis Sci (2003) 1.05
Reversing the Warburg effect as a treatment for glioblastoma. J Biol Chem (2013) 1.02
Soluble CD44 is cytotoxic to trabecular meshwork and retinal ganglion cells in vitro. Invest Ophthalmol Vis Sci (2005) 1.02
A glaucoma-associated mutant of optineurin selectively induces death of retinal ganglion cells which is inhibited by antioxidants. Invest Ophthalmol Vis Sci (2007) 1.02
Estrogen receptor beta as a mitochondrial vulnerability factor. J Biol Chem (2009) 1.02
Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke. J Pharmacol Exp Ther (2009) 1.02
Mechanistic investigations on the antioxidant action of a neuroprotective estrogen derivative. Steroids (2007) 1.02
Rapid mitochondrial dysfunction mediates TNF-alpha-induced neurotoxicity. J Neurochem (2015) 1.01
Neuroprotective effects of a novel non-receptor-binding estrogen analogue: in vitro and in vivo analysis. Stroke (2002) 1.01
A prototypical Sigma-1 receptor antagonist protects against brain ischemia. Brain Res (2007) 0.99
Neuroprotective actions of methylene blue and its derivatives. PLoS One (2012) 0.99
Kidney cancer, version 2.2014. J Natl Compr Canc Netw (2014) 0.98
Metabolic syndrome: a challenging health issue in highly urbanized Union Territory of north India. Diabetol Metab Syndr (2010) 0.97
Subcellular distribution of native estrogen receptor alpha and beta subtypes in cultured human lens epithelial cells. Exp Eye Res (2004) 0.97
Metastatic potential of tumor-initiating cells in solid tumors. Front Biosci (Landmark Ed) (2011) 0.97
Penile cancer: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2013) 0.97
Levels of fatigue and distress in senior prostate cancer survivors enrolled in a 12-week randomized controlled trial of Qigong. J Cancer Surviv (2013) 0.96
Dose dependence and therapeutic window for the neuroprotective effects of 17beta-estradiol when administered after cerebral ischemia. Neurosci Lett (2007) 0.96
Glutamate receptor activation evokes calpain-mediated degradation of Sp3 and Sp4, the prominent Sp-family transcription factors in neurons. J Neurochem (2007) 0.96
Multidrug-resistant MCF-7 breast cancer cells contain deficient intracellular calcium pools. Breast Cancer Res Treat (2002) 0.96
The use of estrogens and related compounds in the treatment of damage from cerebral ischemia. Ann N Y Acad Sci (2003) 0.95
The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Target Oncol (2013) 0.95
Role of protein phosphatases in estrogen-mediated neuroprotection. J Neurosci (2005) 0.95
Sequencing systemic therapies for metastatic kidney cancer. Curr Treat Options Oncol (2015) 0.95
The effect of atrazine administered by gavage or in diet on the LH surge and reproductive performance in intact female Sprague-Dawley and Long Evans rats. Birth Defects Res B Dev Reprod Toxicol (2014) 0.93
Methylation of AR locus does not always reflect X chromosome inactivation state. Blood (2012) 0.93
The role of CaMKII in BDNF-mediated neuroprotection of retinal ganglion cells (RGC-5). Brain Res (2005) 0.92
Estrogen protection in Friedreich's ataxia skin fibroblasts. Endocrinology (2011) 0.92
Neuroprotective effects of minocycline against in vitro and in vivo retinal ganglion cell damage. Brain Res (2005) 0.92
Heat shock protein 27 delays Ca2+-induced cell death in a caspase-dependent and -independent manner in rat retinal ganglion cells. Invest Ophthalmol Vis Sci (2005) 0.91
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res (2013) 0.91
Neuroprotective effects of PPARgamma agonists against oxidative insults in HT-22 cells. Eur J Pharmacol (2003) 0.91
Neuroendocrine mechanism for tolerance to cerebral ischemia-reperfusion injury in male rats. J Neurobiol (2005) 0.91
Estrogens as protectants of the neurovascular unit against ischemic stroke. Curr Drug Targets CNS Neurol Disord (2005) 0.91
Empirically identified goals for the management of unexplained symptoms. Fam Med (2006) 0.90
A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer (2014) 0.90
An okadaic acid-induced model of tauopathy and cognitive deficiency. Brain Res (2010) 0.90
Management of cancer-associated thrombotic microangiopathy: what is the right approach? Am J Hematol (2007) 0.90
Microarray reveals complement components are regulated in the serum-deprived rat retinal ganglion cell line. Mol Vis (2007) 0.89
Proestrus levels of estradiol during transient global cerebral ischemia improves the histological outcome of the hippocampal CA1 region: perfusion-dependent and-independent mechanisms. J Neurol Sci (2002) 0.89
Estrogen receptor-independent neuroprotection via protein phosphatase preservation and attenuation of persistent extracellular signal-regulated kinase 1/2 activation. J Pharmacol Exp Ther (2007) 0.89
Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev (2013) 0.89
IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys (2010) 0.88
Cell-cycle regulators are involved in transient cerebral ischemia induced neuronal apoptosis in female rats. FEBS Lett (2005) 0.88
Ethanol withdrawal posttranslationally decreases the activity of cytochrome c oxidase in an estrogen reversible manner. Neurosci Lett (2007) 0.88
Estradiol protects against cerebellar damage and motor deficit in ethanol-withdrawn rats. Alcohol (2002) 0.88
Management of castrate resistant prostate cancer-recent advances and optimal sequence of treatments. Curr Urol Rep (2013) 0.88
Okadaic acid induces tau phosphorylation in SH-SY5Y cells in an estrogen-preventable manner. Brain Res (2010) 0.87
Estrogen treatment following severe burn injury reduces brain inflammation and apoptotic signaling. J Neuroinflammation (2009) 0.87
The assessment of non-feminizing estrogens for use in neuroprotection. Brain Res (2010) 0.87